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Our aim was to review the evidence related to the impact of co-morbid severe mental illness SMI 19 
(schizophrenia, schizoaffective and bipolar disorder) and HIV upon mental health, physical health and 20 
social outcomes. We carried out a systematic review of scientific evidence, searching online databases 21 
(MEDLINE, PsychInfo, EMBASE, Global Health and Scopus) for studies between 1983 and 2017 using 22 
search terms for SMI and HIV. Studies were included if they compared health or social outcomes 23 
between people living with co-morbid SMI and HIV and people living with either: a) HIV only; or b) SMI 24 
only. Outcomes of interest were: mortality, health service use, HIV/SMI-related, co-morbidities, and 25 
social outcomes. We identified 20 studies which met our inclusion criteria. Although studies were 26 
generally high quality, there was heterogeneity in both selection of outcomes and choice of measure. It 27 
was therefore difficult to draw strong conclusions regarding the impact of co-morbid SMI and HIV across 28 
any outcome. We found little evidence that co-morbid SMI and HIV were associated with lower levels of 29 
treatment, care or poorer clinical outcomes compared to people living with SMI or HIV alone. However, 30 
mortality appeared to be higher among the co-morbid group in two out of three studies. Physical and 31 
mental co-morbidities and social outcomes were rarely measured. Limited data mean that the impact of 32 
co-morbid SMI and HIV is uncertain. In order to develop evidence-based guidelines, there is an urgent 33 
need for further research. This may be realized by exploring opportunities for using data from existing 34 
cohort studies, routinely collected data and data linkage to investigate important questions relating to 35 
this neglected but potentially important area. 36 
Systematic review; schizophrenia; bi-polar disorder; schizoaffective disorder; HIV; comorbidity  37 
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Introduction 38 
Despite availability of highly effective treatments, both HIV and SMI are associated with high levels of 39 
avoidable morbidity and mortality [1, 2]. Although HIV and SMI are serious chronic conditions, when 40 
optimally managed individuals are able to live largely free of disability and illness. However, there is now 41 
significant evidence of health inequalities associated with each condition, resulting in greatly increased 42 
risk of mortality for some groups.  People living with SMI have double the risk of mortality compared to 43 
the general population (pooled relative risk=2.2 [3] and starting antiretroviral therapy (ART)  with a CD4 44 
count of less than 350 cells/µL is associated with 15 years loss of life [1]. A recent systematic review 45 
estimated that the rate of HIV among people living with SMI in the USA was ten times that of the 46 
general population, at 6.0% versus 0.6% [4]. The pooled prevalence for studies carried out in African 47 
settings was even higher at 19%, suggesting that the global burden of people with SMI and HIV could be 48 
significant [4].  49 
Very little is known about the impact of SMI and HIV co-morbidity. We could identify no previous 50 
systematic reviews about health and social outcomes of people living with SMI and HIV. Research 51 
indicates that similar challenges inhibit positive patient outcomes across both conditions. Both 52 
conditions require high levels of adherence for treatment to be effective[5]. For people with 53 
schizophrenia, rates of partial adherence or non-adherence are estimated to be at least 40-50%, with 54 
rates worsening over time [6]. Rates for adherence to ART tend to be higher; a recent systematic review 55 
identified pooled ART adherence rates of 86% for people living in lower income countries and 68% for 56 
people living in higher income countries[7]. Some of the same barriers apply to adherence to medication 57 
for both conditions: alcohol and substance use; side effects; lack of social support; difficulties accessing 58 
treatment; transportation; resources to buy medication; patient experience of the health services 59 
including relationships with staff [6, 8].  Although people with SMI have much higher rates of death from 60 
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suicide and other unnatural causes, the vast majority of excess mortality is due to those conditions 61 
which are the most common cause of death among the general population[9, 10]. Similarly, although 62 
AIDS-related causes account for around a third of deaths among people living with HIV/AIDS [11], PLHA 63 
are at higher risk of non-communicable diseases (NCDs) such as cancers, liver disease and cardiovascular 64 
disease which account for 40% of deaths [11]. As in the general population, risk factors are multifactorial 65 
and include lifestyle factors such as smoking, alcohol and drug-use[9]. However, both long-term ART use 66 
and use of anti-psychotics are associated with metabolic changes linked to NCDs. Finally, research 67 
suggests that the accumulation of difficulties associated with living with HIV or with SMI result in worse 68 
social outcomes for some of those affected. A large body of evidence suggests that between 25 and 60% 69 
of people living with SMI have substance use or dependency on drugs and alcohol [12, 13] and that this 70 
co-morbidity is associated with multiple challenges regarding management, including recurrent 71 
presentation at services, higher rates of social problems and relapse [13]. 72 
Given the evidence of risk of poor outcomes for each condition [10, 14] we would argue that the lack of 73 
research in this area is a significant concern. There are currently no internationally agreed guidelines to 74 
support the management of co-morbidity [15]. Given the challenges associated with the management of 75 
each condition; additional complexity associated with co-morbidity is likely to be significant. However, 76 
excess risk associated with co-morbidity is likely to be modifiable [9].  The aim of this systematic review 77 
is to synthesize existing evidence, using the syndemic paradigm to frame our work providing a platform 78 
for further research and possible guideline development.   79 
Methods 80 
Search Strategy 81 
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The Preferred Reporting items for reviews guideline was adopted in this study [16].  The protocol for the 82 
study was registered with an international prospective register for systematic reviews- PROSPERO 83 
(http://www.crd.york.ac.uk/prospero/display_record.asp?src=trip&ID=CRD42016037284).  84 
Our scoping searches revealed the relatively small size of the evidence-base, we therefore agreed upon 85 
a pragmatic decision to group together study participants with a diagnosis of schizophrenia, 86 
schizoaffective disorder or bipolar disorder as having “severe mental illness” (SMI). This categorization is 87 
commonly used by researchers in this area and has a strong theoretical basis, given that these are the 88 
most frequently diagnosed disorders which are likely to result in persistent, disabling illness resulting in 89 
a need for specialized psychiatric treatment (in-patient and out-patient) in settings where these services 90 
are available [17, 18]. On the 21st of June 2016, we searched five online databases including MEDLINE, 91 
PsycINFO, EMBASE, Global Health and Scopus. The search was updated on the 19th June 2017 to include 92 
studies conducted after the initial search. The search terms ‘severe mental illness’ (its synonyms and 93 
related terms including schizophrenia*, bipolar disorder, psychosis, schizoaffective and severe mental 94 
disorder*) and ‘human immunodeficiency virus’. We also searched within the references of the studies 95 
identified by our search of databases. See Table 1 for eligibility criteria. The rationale for the date of 96 
publication criteria is derived from the date of publication of the first study to identify HIV as the cause 97 
of AIDS [19].  98 
Data collection and analysis 99 
The study selection was based on eligibility criteria set out in the protocol registration. The search was 100 
conducted by IE and RM and the results from the databases exported to Endnote X7, which was also 101 
used to eliminate duplicate studies.  An initial screening of abstract and titles was conducted by IE using 102 
the eligibility criteria and was double-screened by RP. The selected articles for full text review were 103 
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retrieved and reviewed by IE while RM, DO and CT independently reviewed the identified articles. A final 104 
list of 20 articles was selected by consensus by IE, RM, DO and CT (see Figure 1).  105 
Data including author, year of publication, country of publication, study design, study population and 106 
background, outcome variables and statistical methods were extracted into an excel sheet by IE and RM. 107 
The extracted material was reviewed together by IE, RM, DO and CT in three review sessions. Quality 108 
assessment of studies was conducted by IE using the Quality Assessment Tool for Systematic Reviews of 109 
Observational Studies (QATSO)[20] as used by Hughes and colleagues [4].  Domains and rules for scoring 110 
were as follows: clear definition of SMI/HIV population (No=0,Yes=1);Response rate (≤60% or not 111 
reported=0, >60%=1; whether study controlled for confounding through matching, restriction or 112 
adjustment (No/if descriptive=0,Yes=1); sample size (<200 participants=0,≥200 participants=1), giving a 113 
score of 0-4. Outcomes of quality assessment are described in Table 2. We did not exclude studies on 114 
the basis of quality.   115 
The study was exploratory and the studies included were heterogeneous in terms of design, 116 
populations, selected outcomes and measures. We therefore conducted a narrative synthesis based on 117 
the study objectives. 118 
Results 119 
We identified 20 studies in total which met our inclusion criteria (see Table 2) and the total number of 120 
study participants was 8,788,290 (sample size ranged from 27 to 5,901,621). However, some studies 121 
used the same data sources: eg. One group of authors carried out cross-sectional followed by 122 
longitudinal analyses of participants in HIV Research Network Sites [21, 22]. In the following cases, 123 
overlap in samples cannot be ruled out: HIV-only comparison groups were obtained from the HIV Costs 124 
and Services Utilisation Study for two studies [23, 24]; two studies used Veteran’s Health Association 125 
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data (analysing different outcomes) [25, 26]; two studies used Medicaid data from a similar time period 126 
[27, 28], (a further study used Medicaid data from a different time period- [29] and a group of authors 127 
carried out complimentary analyses- different time periods, new healthcare cost estimates, using 128 
Medicaid data [30, 31]; two studies recruited participants from the same hospital site (Butabika National 129 
Referral Hospital, Uganda) during similar time periods but analysed different outcomes [32, 33]. 130 
Thirteen studies were cohorts while the remaining seven were cross-sectional. Eight studies compared 131 
outcomes between people living with SMI and HIV and those living with SMI only [25, 27, 32, 34-38] and 132 
16 studies compared outcomes between people living with SMI and HIV and those living with HIV only 133 
[21, 23, 24, 27, 29, 35-37, 39-46]. 17 studies were carried out in the USA, six of which consisted of 134 
analysis of health insurance claims records data [25, 27, 29, 34, 36, 37]. Studies from outside of the USA 135 
included: a large population-based cohort study from Denmark [35] using linked registries; two clinical 136 
cohort studies from Uganda [32, 43]; a small clinical study carried out in Italy [46].   137 
A high proportion of studies selected for inclusion were judged to be of good quality (81% (n=16)) 138 
scoring 3-4 overall on the quality assessment, with large sample sizes, good retention and clear 139 
definition of exposure groups (see Table 2). The most common reason for scoring less than the 140 
maximum of 4 was no adjustment for confounders.  141 
Outcomes measured included the following: mortality, suicidality, AIDS-defining illness, ART 142 
use/discontinuation/adherence, health service use, costs, receipt of care (as described below and in 143 
Table 2). 144 
Mortality 145 
Three studies examined mortality. Two studies found that people with SMI and HIV had an elevated risk 146 
of death compared to those living with HIV alone (MMR=76.5, 95% CI=44-122, compared to HIV only 147 
MMR=47.2, 95% CI=41-54 [47]; and adjusted hazard ratio=1.40, 95% CI=1.11-1.77)[26]. In the same 148 
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study, although risk of death was higher for people living with schizophrenia compared to those without 149 
a mental disorder, risk of death was further elevated for the group with SMI and HIV across the two time 150 
periods considered[26]. However, in their analysis of Medicaid records from Maryland USA Chander et 151 
al found no difference in mortality between people living with SMI and HIV and those living with SMI 152 
alone [28].  153 
Suicidality 154 
Two studies examined suicidality. A cross-sectional study carried out among psychiatric inpatients at an 155 
urban hospital in the USA found that those patients with SMI and HIV were more likely to have suicidal 156 
ideation [38]. However, a larger longitudinal study carried out using a national inpatient database found 157 
that although people living with psychosis and HIV had no increased risk of suicide attempts/self-158 
inflicted injuries compared with those without a diagnosis of SMI (AOR=1.28, 95% CI=0.84-1.96); those 159 
with psychosis alone had elevated odds of suicidality (AOR=1.73, 95% CI=1.64-1.82)[48]. In the same 160 
study, a similar pattern was found for non-adherence to medical treatment.   161 
HIV-related factors 162 
Four studies examined AIDS-defining illness. None of the three studies carried out in the USA found a 163 
difference in the incidence of AIDS-defining illnesses between people with SMI and HIV and those living 164 
with HIV alone [26, 28, 45]. However, in their Ugandan sample, Nachega et al found that people with 165 
SMI and HIV were more likely to be diagnosed with HIV-related dementia and wasting syndrome 166 
compared to those with HIV alone, although there was no difference in the odds of having 167 
toxoplasmosis[33].  168 
Nine studies examined various factors related to ART use. Three out of four studies found no evidence 169 
of a difference in ART use between people living with SMI and HIV and those living with HIV alone [23, 170 
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29, 45]. The exception to this was a small study carried out in Italy (n=27) which found that those with 171 
new-onset psychosis were less likely to be using ART than those with HIV only [46]. Although Himelhoch 172 
et al (2007) found no evidence of a difference in ART use between those with SMI and HIV and those 173 
with HIV alone, they did find that those with SMI and HIV and co-morbid Injecting Drug Use (IDU) were 174 
less likely to be in receipt of ART than those living with HIV alone (AOR=0.52 (95% CI=0.41-0.81) [22]. In 175 
a Danish study using linked data registries, during the earlier study period people living with HIV and 176 
schizophrenia were found to be less likely to initiate ART (IRR=0.42, 95% CI=0.13-0.99) during the later 177 
period there was no evidence of a difference between groups [47]. In their study using data from HIV 178 
Research Network sites, Himelhoch et al (2009) found that people with SMI and HIV were less likely to 179 
discontinue ART than the HIV alone group during the first two years of treatment only [49]. Among 180 
Ugandan patients, Nachega et al (2013) found that SMI and HIV was associated with increased odds of 181 
discontinuation of ART (adjusted hazard ratio=1.58, 95% CI=1.06-2.33)[33]. An analysis of New Jersey 182 
Medicaid records found there was no evidence of a difference in time on ART between those with SMI 183 
and HIV and HIV alone [29]. Finally, a small study which compared adherence to ART between people 184 
with bi-polar disorder and HIV and HIV alone found that adherence was worse for the bipolar and HIV 185 
group across both measures administered [42]. 186 
Health service use and associated costs 187 
Seven studies examined health service use, costs or receipt of HIV care. Analysis of data from HIV 188 
Research Network sites in the USA showed that people living with SMI and HIV had increased odds of 189 
inpatient medical hospitalisation compared to HIV alone (AOR=1.70, 95% CI=1.34-2.15) [22]. Those with 190 
IDU in addition to SMI and HIV had further increased the odds of an inpatient episode (AOR=2.22, 95% 191 
CI=1.64-3.01), compared to those with HIV alone[22]. Contrastingly, in an analysis carried out using data 192 
from a multisite study, Rosenberg et al (2005) found that people with SMI and HIV had a lower mean 193 
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number of hospitalisations, as compared with people living with SMI alone [25]. In the same study, the 194 
SMI and HIV group were also less likely to have had recent experience of being arrested, jailed or 195 
homelessness compared to those with SMI alone. In a series of studies examining health service use and 196 
associated costs among Medicaid patients in Philadelphia, Rothbard et al consistently found that people 197 
living with SMI and HIV had higher rates of health service use than the SMI alone and HIV alone groups 198 
and consequently higher associated costs[27, 36, 37]. Fremont et al (2007) found that people with SMI 199 
and HIV were more likely to report problems with HIV related medical care [24]. Bogart et al found that 200 
people living with SMI and HIV were as likely as people with HIV alone to receive adequate HIV 201 
monitoring [23].  202 
Other co-morbidities 203 
Nine studies examined other co-morbidities, most commonly drug use (n=6). Findings suggest that 204 
compared to people living with HIV alone, people with SMI and HIV are more likely to have a history of 205 
IDU [21], report recent heroin/cocaine use [24] or abuse drugs and alcohol [40]. Drug and alcohol-206 
related disorders and disability were also more common among people with SMI and HIV compared to 207 
people living with SMI alone [30]. Two small studies found that people with bi-polar disorder and HIV 208 
were more likely to report methamphetamine use, compared to those living with HIV only [42, 45]. In 209 
their analysis of Maryland Medicaid records, Chander et al found that people with SMI and HIV had a 210 
higher prevalence of chronic obstructive pulmonary disease, compared to people living with HIV alone 211 
but there were no differences between groups in the prevalence of other chronic diseases[40] . 212 
In their study carried out among inpatients at two tertiary psychiatric hospitals in Uganda, Nakasujja et 213 
al (2012) found that people with SMI and HIV had worse overall cognition (at baseline and follow-up, 214 
after adjusting for sociodemographic characteristics) and across all domains (after adjusting for all other 215 
cognitive co-variates) compared to those with SMI only [32].Lastly, a small study found that people with 216 
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bi-polar disorder and HIV were more likely to be impaired across three out of four cognitive domains 217 
(visuospatial, recall, verbal recall performance), as compared to people with HIV alone [39]. 218 
Discussion 219 
We found insufficient evidence to fully assess whether HIV and SMI have a syndemic effect. The overall 220 
number of studies identified was small. Although studies were generally high quality, there was 221 
heterogeneity in both selection of outcomes and choice of measure. It was therefore difficult to draw 222 
strong conclusions regarding the impact of co-morbid SMI and HIV across any outcome. Given that the 223 
health systems context is likely to be an important mediator of impact, the fact that almost all studies 224 
were carried out in the USA is a major limitation to generalisability of our findings. Nonetheless, our 225 
findings are important in terms of both highlighting gaps in the evidence-base, as well as providing an 226 
indication for future priority areas for research.  227 
We found some evidence that SMI and HIV co-morbidity might be associated with elevated mortality: 228 
the two studies which compared mortality of people living with SMI and HIV with that of people living 229 
with HIV alone found that the co-morbid group had an increased risk of death. The study where people 230 
living with SMI alone were the comparison group found no evidence of a difference in risk between the 231 
co-morbid and the SMI-only group. The strongest evidence came from the highest quality study included 232 
in the review a Danish cohort using linkage of national registries of psychiatric illness and HIV 233 
(n=2,646,154). This study compared mortality for people living with schizophrenia and schizophrenia 234 
and HIV to people without either condition. Its findings were a  greatly elevated mortality for both 235 
groups which was highest among people living with SMI and HIV, (MMR=76.5, 95% CI=44-122) 236 
compared to the general population [35]. Further research in settings outside of Denmark and the USA 237 
is necessary to explore the generalisability of these findings. It will be important to examine cause of 238 
death in order to understand the underlying mechanisms for the mortality findings. 239 
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We anticipated that our systematic review might reveal the impact of co-morbidity upon factors on the 240 
causal pathway to early mortality. However, evidence relating to navigation of the cascade of care, 241 
health service use, adherence and co-morbidities was scarce. There was a reasonable body of evidence 242 
examining various aspects of ART use (n=9). With the exception of two studies from Uganda, we found 243 
very little evidence of differences in navigation of the continuum of care between people living with co-244 
morbid SMI and HIV and people living with HIV alone. Although the evidence base was sparser, results 245 
examining adherence to medical care comparing the co-morbid group with people living with SMI along 246 
seemed to suggest no difference between groups, whilst two studies suggested that those living with co-247 
morbidity might have better outcomes than those living with SMI or HIV alone. Although symptoms 248 
associated with living with HIV and SMI might inhibit effective navigation of healthcare, in the USA, 249 
people living with HIV are eligible for support from various public programmes, which mean that the 250 
mental and physical healthcare services they access are more likely to be co-located [21]. Results of 251 
other studies carried out in the USA which suggested that people living with co-morbid SMI and HIV had 252 
elevated health service use and associated costs, as well as being less likely to have adverse social 253 
outcomes are consistent with this [25, 27, 30, 31]. Given differences in health systems, it is unlikely that 254 
results are generalizable to other settings. Differences are likely to be particularly stark for people living 255 
with co-morbid SMI and HIV in low income country settings where health systems are over-stretched 256 
and where those with SMI arguably experience greater stigma [50]. 257 
Finally, there was very little research regarding the prevalence and impact of mental and physical co-258 
morbidities among people living with co-morbid SMI and HIV. There are several reasons why it is 259 
important to improve understanding in this area. Firstly, our research is consistent with the established 260 
evidence that suggests that co-morbid substance use is common among people living with SMI. The 261 
impact of this additional co-morbidity, including associations with social outcomes, is under-researched. 262 
Second, NCDs now account for the majority of deaths among both people living with HIV and those 263 
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living with SMI [51]. Third, both HIV treatment and treatment for SMI are associated with increased risk 264 
factors for NCDs [52, 53]. Finally, risk factors for NCDs among this population are likely to be modifiable 265 
as they are among the general population, albeit with additional complexity and barriers among this 266 
group. Our tentative findings that mortality may be elevated among the SMI and HIV group in some 267 
settings adds to the argument for NCDs to be a priority area for future research.  268 
Our findings were limited by the size of the evidence-base. Heterogeneity of outcomes and measures 269 
eliminated the possibility of meta-analysis, meaning that uncertainty remains regarding the scale of 270 
increased risk for any outcome. Although we did not set limits based on language of publication, the fact 271 
that our search strategy is likely to only identify articles with an abstract published in English is a 272 
possible limitation of our design. Likewise, it is possible that we missed articles which were published in 273 
grey literature as this was not included in our searches. We feel that these limitations are unlikely to 274 
have had a significant impact upon findings. 275 
Further research is necessary in order to understand the true impact of SMI and HIV upon physical and 276 
mental health and social outcomes and in order to assess whether this cluster of disease is syndemic. 277 
There are undeniable barriers to carrying out research among this group. We would therefore 278 
recommend that the best route forward for research in this area is to make use of study designs which 279 
use high quality routine data to explore relevant questions. Arguably, the growth of the use of health 280 
service records for research purposes makes this increasingly feasible.  Gaining a better understanding 281 
of the problem across diverse settings and patient groups is an essential pre-requisite to the 282 
development of evidence-based guidelines for the management of co-morbid SMI and HIV. It will be 283 
important to explore differences between countries in future evidence syntheses, wherein an expanded 284 
evidence base may support meta-analysis to give a more definitive explanation about the extent to 285 
which the impact of co-morbidity differs by health system and sociocultural setting. Likewise, it will be 286 
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important to explore differences in impact across different mental disorder diagnostic groups. The need 287 
for further research is therefore urgent, in order to improve the outcomes for this neglected group.  288 
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Table 1. Study Eligibility Criteria 
 Inclusion Criteria Exclusion 
Study Design RCT, non-randomized controlled trials, 
cross sectional studies, cohort studies 
and case-control. 
Case reports/series, editorials, opinion 




January 1983 to June 2017 Studies where data collection ended 
before January 1983 
Language All Languages None 
Type of Research Quantitative  None 
Study Population Our population of interest is adults 
living with HIV and SMI. We only 
included studies which recruited: a) 
people with diagnosed HIV and SMI- 
(see criteria below) AND b) a control 
group- either: people living with SMI 
and no diagnosed HIV; OR, people 
living with HIV and no diagnosed SMI 
Definition of SMI: diagnosed according 
to either ICD10 or DSM V diagnostic 
categories. Definition includes: those 
illnesses which are associated with 
psychotic symptoms (schizophrenia and 
schizoaffective disorder), and bi-polar 
disorder: these are illnesses with a 
prolonged duration requiring long-term 
treatment; which are severe enough to 
result in significant disability (17). 
Definition of HIV: diagnosed with HIV  
Adolescents/children under 18 years, 
diagnosis of Common Mental Disorder 
only (i.e. Depression without psychotic 














Mortality; suicidal ideation or attempts  
Health service use: inpatient 
admissions, outpatient visits; 
healthcare costs  
Mental health related: psychotropic 
medication use, adherence; cognition; 
symptom severity 
Co-morbidities: non-communicable 
diseases- cardiovascular disease, 






Health service use: inpatient 
Other outcomes 
admissions, outpatient visits; 
healthcare costs 
HIV-related: disease stage/severity - 
CD4 count, viral load, opportunistic 
infections; cognitive impairment/HIV-
related dementia; ART use, initiation, 
adherence, discontinuation 
Co-morbidities: non-communicable 
diseases- cardiovascular disease, 
metabolic disorders, substance use, 
depression 
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5,901,621 Psychosis  ✓     4 
Blackstone et al. 
2012  




     ✓ 2 
Bogart et al. 2006  USA Cross Sectional Service-
users 
880 SMI**    ✓ ✓  4 




623 SMI ✓  ✓   ✓ 4 
Fremont et al. 2007  USA Cross Sectional Service-
users  
295 SMI     ✓ ✓ 4 




2,646,154 Schizophrenia ✓   ✓   4 
Himelhoch et al. 
2007  
USA Cross Sectional Service-
users 
5119 SMI    ✓ ✓  4 






4989 SMI    ✓  ✓ 4 




   ✓  ✓ 3 
Nachega et al. 2013  Uganda Cohort 
(Retrospective) 
Outpatients 773 SMI 
 
  ✓ ✓   3 




478 SMI      ✓ 3 








✓  ✓    4 
  *ART= Antiretroviral Therapy 








  ✓ ✓  ✓ 1 
Ronchi et al. 2000  Italy Cross Sectional Service-
users 
27 Psychosis    ✓   1 
Rosenberg et al. 
2005  




777 SMI     ✓  3 







60503 SMI     ✓ ✓ 3 
Rothbard et al. 2009 
a. 







125027 SMI     ✓  3 
Rothbard et al. 2009 
b. 







23729 SMI     ✓  3 







7744 SMI    ✓   4 
Wood et al 1997 USA Cohort Inpatients 322 SMI  ✓     2 
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